Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Wu, Yi-Long, Prof, Lee, Jin Soo, MD, Thongprasert, Sumitra, MD, Yu, Chong-Jen, Prof, Zhang, Li, Prof, Ladrera, Guia, MD, Srimuninnimit, Vichien, MD, Sriuranpong, Virote, MD, Sandoval-Tan, Jennifer, MD, Zhu, Yunzhong, Prof, Liao, Meilin, Prof, Zhou, Caicun, MD, Pan, Hongming, MD, Lee, Victor, FRCR, Chen, Yuh-Min, PhD, Sun, Yan, MD, Margono, Benjamin, PhD, Fuerte, Fatima, MD, Chang, Gee-Chen, MD, Seetalarom, Kasan, MD, Wang, Jie, Prof, Cheng, Ashley, MBBS, Syahruddin, Elisna, PhD, Qian, Xiaoping, MD, Ho, James, MD, Kurnianda, Johan, SPPD, Liu, Hsingjin Eugene, MD, Jin, Kate, MD, Truman, Matt, MSc, Bara, Ilze, MD, Mok, Tony, Prof
Published in The lancet oncology (01.07.2013)
Published in The lancet oncology (01.07.2013)
Get full text
Journal Article
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
Smith, Katherine E R, Pritzl, Stephanie L, Yu, Wei, Bara, Ilze, Thanarajasingam, Gita, Kaul, Monika D, Williams, Kirstin A, Dueck, Amylou C, Mansfield, Aaron S
Published in JTO clinical and research reports (01.12.2023)
Published in JTO clinical and research reports (01.12.2023)
Get full text
Journal Article